Letrozol AbZ 2,5 mg

Description

Contraindications to the use of letrozole

• Endocrine conditions specific to the reproductive period;
• pregnancy;
• lactation (breastfeeding);
• Infancy (efficacy and safety in children has not been established);
• hypersensitivity to the components of the drug.

Caution: the drug should be used in cases of lactase deficiency, lactase intolerance, glucose-galactose malabsorption syndrome. There are no data on the use of letrozole in patients with a CK < 30 ml/min (the ratio of potential risk to expected treatment effect should be carefully considered before prescribing the drug to such patients).

Method of administration

• The drug is taken orally, irrespective of meals.
• The recommended dose of letrozole is 2.5 mg once/day, daily, long-term (for 5 years or until relapse).
• As extended adjuvant therapy, treatment should be continued for 4 years (not more than 5 years).
• Letrozole should be discontinued if there are signs of disease progression.
• In patients with end-stage or metastatic cancer, treatment with letrozole should be continued as long as there is tumour progression.
• No dose adjustment of letrozole is required in elderly patients.
• No dose adjustment is required for hepatic or renal impairment (CK >10 ml/min). However, in cases of severe hepatic impairment (Child-Pugh class C), patients require continuous medical supervision.
• Use of letrozole during pregnancy and lactation
  Contraindicated use during pregnancy and lactation (breastfeeding).